Mithra Pharmaceuticals SA MITRA.BR Open Mithra Pharmaceuticals SA in new tab
Mithra Pharmaceuticals SA Analysis (MITRA.BR)
Is Mithra Pharmaceuticals SA a good investment? Mithra Pharmaceuticals SA (MITRA.BR) is currently trading at 0.2160 EUR.
Investor FAQ
Does Mithra Pharmaceuticals SA pay a dividend?
No, it does not currently pay a dividend.
What asset class is Mithra Pharmaceuticals SA?
Mithra Pharmaceuticals SA is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
Company Profile
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.
Dividends
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion